News & Updates

Stay up to date with the events unfolding around Spectral Platforms and our groundbreaking technology. Blog coming soon.

March 27, 2020

Refocusing efforts on SARS CoV19

The InSpector-01 and BloodFAST tools were supposed to roll out this summer.  However, those plans have been impacted by SARS CoV19.

And so, we have started examining ways by which our technologies and skills can be used to impact the epidemic.

May 19, 2018

We are informed by the USPTO of a “notice of allowance” on our patent application “Albumin-based non-covalent complexes and methods of use thereof”

April 10, 2018

Spectral Platforms is one of 10 Step 1 winners on the AMR challenge Winners were announced, 3/27/2017.. 

January 20, 2018

Qsub on InSpector-01 submitted to the FDA

Nov 10, 2017

Clinical study of InSpector-01 ends at US site

March 2, 2017

Company closes Series A3 investment round

Nov 17, 2016

Patent application “Albumin-based non-covalent complexes and methods of use thereof”  published at USPTO site 

Nov 11, 2016

Clinical study of InSpector-01 begins at US site

October 10, 2016

Clinical study of InSpector-01 ends at UK site

August 22, 2015

Clinical study of InSpector-01 begins at UK site

July 5, 2015

Company closes Series A2 investment round

September 22, 2014

Study of InSpector-01 with artificially spiked samples ends at UK site

July 2, 2013

Company closes Series A investment round

Febuary 28, 2013

Patent application “Rapid detection of metabolic activity” published at USPTO site

January, 2013

Initial PreIDE submission on InSpector-01 to the FDA

January, 2012

Initial clinical study on screened biomarker conducted at US site

June 2011

Initial screening of biomarker that can detect/characterize pathogenic microorganisms